Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results?

Leuk Res. 2020 Mar:90:106313. doi: 10.1016/j.leukres.2020.106313. Epub 2020 Feb 4.

Authors

Mariangela Costanza¹, Olivier Spertini², Sabine Blum²

Affiliations

¹ Service and Central Laboratory of Hematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. Electronic address: mariangela.costanza@chuv.ch.
² Service and Central Laboratory of Hematology, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.

PMID: 32058175
DOI: 10.1016/j.leukres.2020.106313

No abstract available

Keywords: JAK1/2 inhibitors; Lymphoma; Myeloproliferative neoplasms.

Publication types

Letter

MeSH terms

Disease Susceptibility
Humans
Incidence
Janus Kinase 1 / antagonists & inhibitors
Janus Kinase 2 / antagonists & inhibitors
Janus Kinase Inhibitors / adverse effects
Janus Kinase Inhibitors / therapeutic use
Lymphoma, B-Cell / epidemiology*
Lymphoma, B-Cell / etiology*
Molecular Targeted Therapy / adverse effects
Molecular Targeted Therapy / methods
Myeloproliferative Disorders / drug therapy
Myeloproliferative Disorders / epidemiology*

Substances

Janus Kinase Inhibitors
Janus Kinase 1
Janus Kinase 2